This is a summary of the European public assessment report (EPAR) for Hirobriz Breezhaler. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Hirobriz Breezhaler.
- What is Hirobriz Breezhaler?
Hirobriz Breezhaler is a medicine that contains the active substance indacaterol. It is available as capsules containing a powder for inhalation (150 and 300 micrograms).
- What is Hirobriz Breezhaler used for?
Hirobriz Breezhaler is used to keep the airways open in adults with chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing air in and out of the lungs.
The medicine can only be obtained with a prescription.
- How is Hirobriz Breezhaler used?
Hirobriz Breezhaler capsules are only used with a Hirobriz Breezhaler inhaler and must not be swallowed. To take a dose, the patient places a capsule into the inhaler and breathes the powder in through the mouth.
The recommended dose is one 150-microgram capsule, once a day at the same time each day. A dose of one 300-microgram capsule may be used in cases of severe COPD, but this must only be done on the doctor’s instructions.
- How does Hirobriz Breezhaler work?
The active substance in Hirobriz Breezhaler, indacaterol, is a beta-2-adrenergic-receptor agonist. It works by attaching to beta-2 receptors that are found in the muscle cells of many organs and that cause the muscles to relax. When Hirobriz Breezhaler is inhaled, indacaterol reaches the receptors in the airways and activates them. This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.
- How has Hirobriz Breezhaler been studied?
In three main studies involving over 4,000 patients with COPD, Hirobriz Breezhaler at different doses has been compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD). The main measure of effectiveness was how Hirobriz Breezhaler compared with placebo in improving patients’ forced expiratory volumes (FEV1) after 12 weeks. FEV1 is the most air a person can breathe out in one second.
- What benefit has Hirobriz Breezhaler shown during the studies?
Hirobriz Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD. On average, the improvement in FEV1 in patients who received Hirobriz Breezhaler was between 150 to 190 ml, while for patients who received placebo the change in FEV1 ranged from a decrease of 10 ml to an increase of 20 ml. Overall, the effects of the 150- and 300-microgram doses of Hirobriz Breezhaler were similar, but the results showed that the 300-microgram dose may provide better relief in patients with more severe disease.
- What is the risk associated with Hirobriz Breezhaler?
The most common side effects with Hirobriz Breezhaler (seen in between 1 and 10 patients in 100) are nasopharyngitis (inflammation of the nose and throat), upper-respiratory-tract infection (colds), sinusitis (inflammation of the sinuses), dizziness, headache, chest pain, cough, oropharyngeal (mouth and throat) pain including throat irritation, rhinorrhoea (runny nose), muscle spasm (cramps) and peripheral oedema (swelling, especially of the ankles and feet). For the full list of all side effects reported with Hirobriz Breezhaler, see the package leaflet.
Hirobriz Breezhaler must not be used in people who are hypersensitive (allergic) to indacaterol, lactose or any of the other ingredients.
- Why has Hirobriz Breezhaler been approved?
The CHMP decided that Hirobriz Breezhaler’s benefits are greater than its risks and recommended that Hirobriz Breezhaler be given marketing authorisation.
- What measures are being taken to ensure the safe use of Hirobriz Breezhaler?
The company that makes Hirobriz Breezhaler will ensure that doctors who are expected to prescribe the medicine and pharmacists in all Member States are provided with a card containing information on how the medicine is used.
- Other information about Hirobriz Breezhaler:
European Commission granted a marketing authorisation valid throughout the European Union for Hirobriz Breezhaler on 30 November 2009.
For more information about treatment with Hirobriz Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This EPAR was last updated on 24/04/2017 .
23/02/2017 Hirobriz Breezhaler -EMEA/H/C/001211 -WS/1102
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Drugs for obstructive airway diseases
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Changes since initial authorisation of medicine
|Name||Language||First published||Last updated|
|Hirobriz Breezhaler : EPAR - Procedural steps taken and scientific information after authorisation||SV = svenska||2010-04-09||2017-04-24|
|Hirobriz Breezhaler-H-C-PSUV-0023 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)||SV = svenska||2016-05-23|
|Hirobriz Breezhaler-H-C-1211-PSU-08 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation||SV = svenska||2013-09-13|
Initial marketing-authorisation documents
|Name||Language||First published||Last updated|
|Hirobriz Breezhaler : EPAR - Public assessment report||SV = svenska||2010-01-05|
|Committee for medicinal products for human use, summary of positive opinion for Hirobriz Breezhaler||SV = svenska||2009-09-25|
This medicine is approved for use in the European Union